SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-007007
Filing Date
2023-03-09
Accepted
2023-03-09 16:05:50
Documents
14
Period of Report
2023-03-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pstx-20230309.htm   iXBRL 8-K 57478
2 EX-99.1 pstx-ex99_1.htm EX-99 213736
3 GRAPHIC img265366334_0.jpg GRAPHIC 25951
  Complete submission text file 0000950170-23-007007.txt   437403

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pstx-20230309_lab.xml EX-101.LAB 13350
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pstx-20230309.xsd EX-101.SCH 2454
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pstx-20230309_pre.xml EX-101.PRE 9830
8 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20230309_htm.xml XML 4723
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 23719733
SIC: 2836 Biological Products, (No Diagnostic Substances)